Effective Use of Bromelain and Acetylcysteine (BromAc

Acetylcysteine bromelain novel therapy pseudomyxoma peritonei

Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 26 07 2023
revised: 05 09 2023
accepted: 06 09 2023
pubmed: 29 9 2023
medline: 29 9 2023
entrez: 29 9 2023
Statut: ppublish

Résumé

Pseudomyxoma peritonei (PMP) is a rare clinical condition of progressive peritoneal mucin accumulation. PMP has a reasonable survivability but with a notable risk of tumour recurrence. Standard treatment, including for tumour relapse, aims for a cure with complete cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. In the case of tumour recurrence, surgery becomes progressively complex, and some patients are not suitable for surgery either due to patient preference or morbidity and mortality risk. BromAc We report the case of a 64-year-old male with a background of appendiceal PMP who presented with a gastric outlet obstruction from a perigastric tumour deposit. This was managed with BromAc BromAc

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Pseudomyxoma peritonei (PMP) is a rare clinical condition of progressive peritoneal mucin accumulation. PMP has a reasonable survivability but with a notable risk of tumour recurrence. Standard treatment, including for tumour relapse, aims for a cure with complete cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. In the case of tumour recurrence, surgery becomes progressively complex, and some patients are not suitable for surgery either due to patient preference or morbidity and mortality risk. BromAc
CASE REPORT METHODS
We report the case of a 64-year-old male with a background of appendiceal PMP who presented with a gastric outlet obstruction from a perigastric tumour deposit. This was managed with BromAc
CONCLUSION CONCLUSIONS
BromAc

Identifiants

DOI: 10.21873/anticanres.16670 PMID: 37772592
pubmed: 37772592
pii: 43/10/4735
doi: 10.21873/anticanres.16670
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4735-4738

Informations de copyright

Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Elizabeth Skalkos (E)

Peritonectomy and Liver Cancer Unit, Department of Surgery, St George Hospital, Kogarah, NSW, Australia; elizabeth.skalkos@health.nsw.gov.au.
Department of Surgery, Faculty of Medicine, The University of New South Wales, Sydney, NSW, Australia.

Kerry L Chen (KL)

Peritonectomy and Liver Cancer Unit, Department of Surgery, St George Hospital, Kogarah, NSW, Australia.
Department of Surgery, Faculty of Medicine, The University of New South Wales, Sydney, NSW, Australia.

Ruwanthi Wijayawardana (R)

Peritonectomy and Liver Cancer Unit, Department of Surgery, St George Hospital, Kogarah, NSW, Australia.

David L Morris (DL)

Peritonectomy and Liver Cancer Unit, Department of Surgery, St George Hospital, Kogarah, NSW, Australia.
Department of Surgery, Faculty of Medicine, The University of New South Wales, Sydney, NSW, Australia.

Classifications MeSH